(Las Vegas Nevada United States), DelveInsight’s, “Respiratory Syncytial Virus (RSV) – Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Respiratory Syncytial Virus Pipeline Report
-
Leading Respiratory Syncytial Virus companies developing novel drug candidates to improve the Food Allergy treatment landscape include GlaxoSmithKline, MedImmune, ReViral, Pfizer, and many others
-
Promising Respiratory Syncytial Virus pipeline therapies in various stages of development include MEDI-8897, Sisunatovi, and many others.
Respiratory Syncytial Virus Overview
Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.
Respiratory Syncytial Virus Pipeline Analysis: Drug Profile
GSK3844766A: GlaxoSmithKline
This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of the development stage for the treatment of Respiratory Syncytial Virus (RSV).
Discover more about the emerging Food Allergy drugs @ Respiratory Syncytial Virus Treatment Drugs
Respiratory Syncytial Virus Pipeline Therapies and Key Companies
-
GlaxoSmithKline
-
MedImmune
-
ReViral
-
Pfizer
-
Sanofi
-
BioComo
And many others
Respiratory Syncytial Virus Pipeline Therapeutics Assessment
Phases
DelveInsight’s Report covers around 10+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
-
Route of Administration
Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
-
Molecule Type
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Respiratory Syncytial Virus Pipeline Report
-
Coverage: Global
-
Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo and many others
-
Key Respiratory Syncytial Virus Pipeline Therapies : GSK3844766A, Nirsevimab, Sisunatovir and many others
Find out more about the Food Allergy treatment options in development @Respiratory Syncytial Virus Clinical Trials
Table of Contents
1. Respiratory Syncytial Virus Introduction
2. Respiratory Syncytial Virus Executive Summary
3. Respiratory Syncytial Virus Overview
4. Respiratory Syncytial Virus Pipeline Therapeutics
5. Respiratory Syncytial Virus Late-Stage Products (Phase III)
6. Respiratory Syncytial Virus Mid-Stage Products (Phase II)
7. Respiratory Syncytial Virus Early Stage Products (Phase I/II)
8. Respiratory Syncytial Virus Preclinical Stage Products
9. Respiratory Syncytial Virus Discovery Stage Products
10. Respiratory Syncytial Virus Therapeutic Assessment
11. Respiratory Syncytial Virus Inactive Products
12 Respiratory Syncytial Virus Collaborations Assessment- Licensing / Partnering / Funding
13. Respiratory Syncytial Virus Unmet Needs
14. Respiratory Syncytial Virus Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services